The global tuberculosis treatment market size was valued at USD 1.7 billion in 2021, registering at a CAGR of 6.1% from 2022 to 2028. Around a third of the world's population has latent TB; persons infected with mycobacterium infection have a 10% chance of getting tuberculosis; although, people with impaired immunity, such as HIV, diabetes, or cigarette addiction, have a greater chance of contracting tuberculosis. On the basis of the severity of the sickness, medicines used to treat TB are classified as first line treatment or second line treatment. First-line therapy topped the drug class sector in 2016 owing to reasons such as increased TB incidence and early illness detection, resulting in a significant number of patients enrolled on first-line diagnosis. Second-line therapy is expected to increase at a higher rate in the medication class sector from 2017 to 2025, owing to reasons such as the increased number of MDR-TB, the rising frequency of hospital-acquired illness, and patients' failure to adhere to their first-line treatment plan. According to a World Health Organization (WHO) study, TB is one of the top causes of mortality globally. In 2015, around 10 million new cases of tuberculosis were reported globally, with around 1.4 million fatalities due to the disease. With the aid of initiatives like Stop TB, WHO and some government agencies are now striving to reduce the worldwide tuberculosis load.

View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/tuberculosis-treatment-market/         

A surge in drug susceptible (DS) tuberculosis (TB), as well as an upsurge in multi-drug resistant (MDR) TB cases and augmented R&D activities toward medication discovery, are expected to drive the Tuberculosis Treatment market expansion. Furthermore, a solid product pipeline for TB medicines, as well as increased government activities in emerging nations for tuberculosis treatment, provide considerable scope for market expansion in the coming years. The TB medicines industry is being driven by the rising frequency of multi-drug resistant tuberculosis. Drug shortages are a serious impediment to the TB drug market, particularly in low- and middle-income nations. Tuberculosis is particularly difficult to treat when it is linked with illnesses like HIV/AIDS and factors like overweight.

The global tuberculosis treatment market is fragmented in terms of drugs, diagnosis, and end-user. In terms of the diagnosis, the market is categorized into nucleic acid tests, laboratory testing, drug susceptibility test, radiography, and other tests. Further, in terms of drugs, the market is classified into first-line drugs which includes Ethambutol (E/EMB), Pyrazinamide (Z/PZA), Streptomycin and Rifabutin (RFB); and second-line drugs which includes Amikacin (AMK), Kanamycin (KM), and Capreomycin (CM). On the basis of end-user, the market is segregated into government & non-government organizations, hospitals & clinics, and others. Hospitals & clinics division are projected to contribute a major share in the global market.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=22377

The global tuberculosis treatment market segmentation:

1) By Class of Drugs: First Line Drugs, Second Line Drugs)

2) By TB: B, Multi-Drug Resistance TB

3) By route of administration: Oral, Parental

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others

Asia Pacific led the market, with a share of 57.4 percent. This is due to the disease's higher incidence, rising prevalence of HIV-TB co-infection, greater public knowledge of the dangers of drug non-compliance, and improved health systems. In terms of API production, China and India are major players in the APAC industry.

There are several industry players working in the tuberculosis treatment market, which include Bayer AG (Germany), AstraZeneca PLC (U.S.), GlaxoSmithKline PLC (U.S.), Eli Lilly And Company (U.S.), Novartis AG (Switzerland ), Lupin Pharmaceuticals Inc. (India), Sandoz International GmbH (Germany), Pfizer Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Sanofi S.A. (France)

About Precision Business Insights:

We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:

Mr. Satya

Precision Business Insights | Toll Free: +1 866 598 1553

Email: [email protected]
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747